Life Sciences

FIH Partners advises EQT on the divestment of Fertin Pharma to Philip Morris International

Learn more

Life Sciences

FIH Partners advised Novo A/S on the agreement to acquire a significant minority stake in Synlab

Learn more

Life Sciences

FIH Partners advised Novo A/S on the acquisition of Sonion

Learn more

Life Sciences

Since the dawn of biotech IPOs in Denmark in the mid-1990s, the partners of FIH Partners have been actively advising pharma, medtech, biotech and medical supplies companies.

Over the years, we have developed a detailed understanding of the commercial, scientific and regulatory drivers and risks associated with operating in the sector.

Examples of our experience in healthcare:

  • Advisor to EQT in the divestment of Fertin Pharma to Philip Morris International
  • Advisor to Novo A/S in the agreement with Cinven and Ontario Teachers’ Pension Plan to acquire a substantial minority equity stake in Synlab
  • Advisor to Novo A/S in the acquisition of Sonion, a global leader in micro-acoustic technologies used for hearing instruments, for in-ear earphones and in specialty headsets, from Altor Fund III
  • Advisor to Ambu, listed on the OMX Nordic exchange, in the acquisition of King Systems, a US subsidiary of UK-listed Consort Medical
  • Advisor to Glycom in the acquisition of Vitalys’ manufacturing facility in Denmark
  • Advisor to ALK-Abelló in several acquisitions, including the acquisition of Artu Biologicals from Dutch-listed company Fornix BioSciences
  • Advisor to Altor Equity Partners in the acquisition of Pulse Medtech from US-based Technitrol
  • The partners of FIH Partners advised AP Møller Maersk on the divestment of Maersk Medical (Unomedical) to Nordic Capital
  • The partners advised the majority shareholder and board of Radiometer in the divestment of the company to US-based Danaher Corporation
  • Also, the partners advised on the IPOs of Bavarian Nordic, Genmab, NeuroSearch and Pharmexa